Ilene Galinsky

13.1k citations

84 papers · 5.3k indexed · 3 hit papers · h-index 32

Impact in

Hematology top 0.1%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 0.2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 52
- Acute Myeloid Leukemia Research 44
- Chronic Myeloid Leukemia Treatments 23
Genetics 25
- Chronic Lymphocytic Leukemia Research 19

Co-authors: Richard M. Stone Daniel J. DeAngelo D. Gary Gilliland Jennifer Clark Martha Wadleigh Donna Neuberg Todd R. Golub Yana Pikman
Journals: Blood (30 papers)Clinical Cancer Research (6 papers)Leukemia (6 papers)Journal of Clinical Oncology (6 papers)Leukemia Research (5 papers)
Partner nations: United States Canada France

In The Last Decade

Ilene Galinsky

79 papers receiving 5.3k citations

Hit Papers

align trajectories log scale

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity 2019 · 613 citations

Peers

Countries citing papers authored by Ilene Galinsky

Since Specialization

Citations

This map shows the geographic impact of Ilene Galinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilene Galinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilene Galinsky more than expected).

Fields of papers citing papers by Ilene Galinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilene Galinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilene Galinsky. The network helps show where Ilene Galinsky may publish in the future.

Co-authors

The 25 scholars most cited alongside Ilene Galinsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ilene Galinsky Line = papers co-authored together Ilene Galinsky links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study Leukemia Research ·Andreas Reiter, Jason Gotlib, Iván Álvarez‐Twöse, Deepti Radia, Johannes Lübke, Priyanka Bobbili, Aolin Wang, Saša Dimitrijević, Erin Sullivan, Juliana Schwaab, Ilene Galinsky, Cecelia Perkins, Wolfgang R. Sperr, Priya Sriskandarajah, Manasi Mohan, Teshawna Badu, Selvam R Sendhil, Mei Sheng Duh, Peter Valent, Daniel J. DeAngelo	2025	0
2	Salinomycin Nanoparticles Induce Ferroptosis and Synergize with the BCL-2 Inhibitor Venetoclax to Promote AML Cell Death Blood ·Suiyang Liu, Wei Ni, Fen Zhu, Basudev Chowdhury, Ilene Galinsky, Matthew S. Davids, Ellen Weisberg, Surender Kharbanda, Richard M. Stone	2024	0
3	Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen Blood Cancer Journal ·Shai Shimony, Hari S. Raman, Yael Flamand, Julia Keating, Jonathan Paolino, Yannis K. Valtis, Andrew E. Place, Lewis B. Silverman, Stephen E. Sallan, Lynda M. Vrooman, Andrew M. Brunner, Donna Neuberg, Ilene Galinsky, Jacqueline S. Garcia, Eric S. Winer, Martha Wadleigh, Richard M. Stone, Jean M. Connors, Daniel J. DeAngelo, Marlise R. Luskin	2024	2
4	Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Clinical Cancer Research ·Evan C. Chen, Helen Gandler, Isidora Tošić, Geoffrey Fell, Ashlee Fiore, Olga Pozdnyakova, Daniel J. DeAngelo, Ilene Galinsky, Marlise R. Luskin, Martha Wadleigh, Eric S. Winer, Rebecca Leonard, Kelsey O'Day, Adrienne de Jonge, Donna Neuberg, A. Thomas Look, Richard M. Stone, David A. Frank, Jacqueline S. Garcia	2022	6
5	Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN Blood ·Andrew A. Lane, Anthony S. Stein, Jacqueline S. Garcia, Jada L. Garzon, Ilene Galinsky, Marlise R. Luskin, Richard M. Stone, Eric S. Winer, Rebecca Leonard, Tariq I. Mughal, Christopher Brooks, Marina Konopleva, Kristen E. Stevenson, Naveen Pemmaraju	2021	27
6	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax Cancer Discovery ·Joan Montero, Jason Stephansky, Tianyu Cai, Gabriel K. Griffin, Lucía Cabal‐Hierro, Katsuhiro Togami, Leah J. Hogdal, Ilene Galinsky, Elizabeth A. Morgan, Jon C. Aster, Matthew S. Davids, Nicole R. LeBoeuf, Richard M. Stone, Marina Konopleva, Naveen Pemmaraju, Anthony Letai, Andrew A. Lane	2016	144
7	Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults Journal of Geriatric Oncology ·K. Rebecca Fega, Gregory A. Abel, Gabriela Motyckova, Alexander E. Sherman, Daniel J. DeAngelo, David P. Steensma, Ilene Galinsky, Martha Wadleigh, Richard M. Stone, Jane A. Driver	2015	20
8	Intensified Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): A Phase II Study from the Dana Farber Cancer Institute (DFCI) ALL Consortium Blood ·Amir T. Fathi, Daniel J. DeAngelo, Kristen E. Stevenson, Jonathan E. Kolitz, Julie Asch, Philip C. Amrein, Eyal C. Attar, David P. Steensma, Martha Wadleigh, Christine Connolly, Ilene Galinsky, Richard M. Stone, Donna Neuberg, Karen K. Ballen	2014	2
9	MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells Cancer Research ·Dina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, Heidi Mills, Li Yin, Hasan Rajabi, Baldev Vasir, Turner Kufe, Katarina Luptakova, Jon Arnason, Caterina Nardella, James D. Levine, Robin Joyce, Ilene Galinsky, Yoram Reiter, Richard M. Stone, Pier Paolo Pandolfi, Donald Küfe, David Avigan	2013	41
10	A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets Clinical Cancer Research ·Sophia Adamia, Benjamin Haibe‐Kains, Patrick M. Pilarski, Michal Bar‐Natan, Samuel Pevzner, Hervé Avet‐Loiseau, Laurence Lodé, Sigitas Verselis, Edward A. Fox, John P. Burke, Ilene Galinsky, Ibiayi Dagogo‐Jack, Martha Wadleigh, David P. Steensma, Gabriela Motyckova, Daniel J. DeAngelo, John Quackenbush, Richard M. Stone, James D. Griffin	2013	79
11	Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells Molecular Cancer Therapeutics ·Helena Mistry, Grace Hsieh, Sara J. Buhrlage, Min Huang, Eunmi Park, Gregory D. Cuny, Ilene Galinsky, Richard M. Stone, Nathanael S. Gray, Alan D. D’Andrea, Kalindi Parmar	2013	138
12	The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia Journal of Clinical Investigation ·Versha Banerji, Stacey M. Frumm, Kenneth N. Ross, Loretta S. Li, Anna C. Schinzel, Cynthia K. Hahn, Rose M. Kakoza, Kwan T. Chow, Linda S. Ross, Gabriela Alexe, Nicola Tolliday, Haig Inguilizian, Ilene Galinsky, Richard M. Stone, Daniel J. DeAngelo, Giovanni Roti, Jon C. Aster, William C. Hahn, Andrew L. Kung, Kimberly Stegmaier	2012	85
13	Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD American Journal of Hematology ·Harshabad Singh, Lillian Werner, Salma Asali, Daniel J. DeAngelo, Karen K. Ballen, Philip C. Amrein, Martha Wadleigh, Ilene Galinsky, Brian M. Wolpin, Joseph Pidala, Donna Neuberg, Edward A. Fox, Richard M. Stone, Eyal C. Attar	2011	7
14	Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Molecular Cancer Therapeutics ·Ellen Weisberg, Hwan Geun Choi, Rosemary Barrett, Wenjun Zhou, Jianming Zhang, Arghya Ray, Erik A. Nelson, Jingrui Jiang, Daisy Moreno, Richard M. Stone, Ilene Galinsky, Edward Fox, Sophia Adamia, Andrew L. Kung, Nathanael S. Gray, James D. Griffin	2010	12
15	Proteomic and Genetic Approaches Identify Syk as an AML Target Cancer Cell ·Cynthia K. Hahn, Jacob E. Berchuck, Kenneth N. Ross, Rose M. Kakoza, Karl R. Clauser, Anna C. Schinzel, Linda S. Ross, Ilene Galinsky, Tina Davis, Serena J. Silver, David E. Root, Richard M. Stone, Daniel J. DeAngelo, Martin Carroll, William C. Hahn, Steven A. Carr, Todd R. Golub, Andrew L. Kung, Kimberly Stegmaier	2009	120
16	Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Molecular Cancer Therapeutics ·Ellen Weisberg, Renee D. Wright, Douglas W. McMillin, Constantine S. Mitsiades, Arghya Ray, Rosemary Barrett, Sophia Adamia, Richard M. Stone, Ilene Galinsky, Andrew L. Kung, James D. Griffin	2008	60
17	MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia PLoS Medicine ·Yana Pikman, Benjamin H. Lee, Thomas Mercher, Elizabeth McDowell, Benjamin L. Ebert, Maricel Gozo, Adam Cuker, Gerlinde Wernig, Sandra Moore, Ilene Galinsky, Daniel J. DeAngelo, Jennifer Clark, Stephanie J. Lee, Todd R. Golub, Martha Wadleigh, D. Gary Gilliland, Ross L. Levine Hit paper breakdown →	2006	1024
18	Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias Leukemia ·Teresa Palomero, Keith McKenna, Jennifer O’Neil, Ilene Galinsky, Richard M. Stone, Kazumi Suzukawa, Eftichia Stiakaki, Maria Kalmanti, Edward A. Fox, Michael A. Caligiuri, Jon C. Aster, A. Thomas Look, Adolfo A. Ferrando	2006	51
19	Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts Leukemia Research ·Jianlin Gong, Shigeo Koido, Yoko Kato, Yasuhiro Tanaka, Dongshu Chen, Anna K. Jonas, Ilene Galinsky, Daniel J. DeAngelo, David Avigan, Donald Küfe, Richard M. Stone	2004	31
20	KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32) Leukemia ·Ross L. Levine, Martha Wadleigh, David Sternberg, Iwona Wlodarska, Ilene Galinsky, Richard M. Stone, Daniel J. DeAngelo, D. Gary Gilliland, Jan Cools	2004	46

About Ilene Galinsky

Ilene Galinsky is a scholar working on Hematology, Genetics, Oncology, Public Health, Environmental and Occupational Health and Rheumatology, having authored 84 papers that have together received 5.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (44 papers), Chronic Myeloid Leukemia Treatments (23 papers), Chronic Lymphocytic Leukemia Research (19 papers), Acute Lymphoblastic Leukemia research (16 papers), CAR-T cell therapy research (10 papers), Protein Degradation and Inhibitors (8 papers), Eosinophilic Disorders and Syndromes (7 papers) and Childhood Cancer Survivors' Quality of Life (7 papers). The work is most often cited by research in Hematology (3.3k citations), Genetics (1.9k citations), Geriatrics and Gerontology (174 citations), Molecular Biology (2.6k citations) and Oncology (969 citations). Ilene Galinsky has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Richard M. Stone, Daniel J. DeAngelo, D. Gary Gilliland, Jennifer Clark, Martha Wadleigh, Donna Neuberg, Todd R. Golub, Yana Pikman, Ross L. Levine and Stephanie J. Lee. Their work appears in journals such as Blood, Clinical Cancer Research, Leukemia, Journal of Clinical Oncology and Leukemia Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact